Wall Street expects Natera to report Q4 2025 revenue of approximately $660.45 million and a loss per share of $0.46, with the stock currently trading at $206.38 against an average analyst price target of $257.20.
Investors are primarily focused on the growth trajectory of Signatera oncology testing volumes and the company's progress toward sustained cash flow positivity. Preliminary results released in January highlighted a record 55% year-over-year surge in oncology tests processed, largely driven by the rapid adoption of molecular residual disease (MRD) testing.
Momentum is further supported by the recent FDA submission for Signatera as a companion diagnostic in muscle-invasive bladder cancer, which could significantly broaden reimbursement coverage in 2026.